Neoadjuvant Nivolumab and Chemotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Retrospective Study

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

(2021) Hossein Borghaei et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant programmed cell death protein 1 inhibitors combined with chemotherapy in resectable non-small cell lung cancer: an open-label, multicenter, single-arm study

(2021) Hongtao Duan et al.   Translational Lung Cancer Research

Neoadjuvant PD-1 inhibitors and chemotherapy for locally advanced NSCLC: A retrospective study.

(2021) Tianxiang Chen et al.   ANNALS OF THORACIC SURGERY

Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center

(2021) Jianquan Zhu et al.   MEDICAL SCIENCE MONITOR

Perioperative safety and feasibility outcomes of stage IIIA-N2 non-small cell lung cancer following neoadjuvant immunotherapy or neoadjuvant chemotherapy: a retrospective study

(2021) Zhangfeng Huang et al.   Annals of Translational Medicine

Pathological response to neoadjuvant therapy with chemotherapy vs chemoradiotherapy in stage III NSCLC. Contribution of IASLC recommendations

(2021) Diego Muñoz-Guglielmetti et al.   World Journal of Clinical Oncology

Lung Cancer 2020

(2020) Brett C. Bade et al.   CLINICS IN CHEST MEDICINE

Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study

(2020) Roy S. Herbst et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC

(2020) Shugeng Gao et al.   Journal of Thoracic Oncology

Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

(2020) Marina C Garassino et al.   LANCET ONCOLOGY

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

(2020) Catherine A Shu et al.   LANCET ONCOLOGY

A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non–Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407

(2020) Luis Paz-Ares et al.   Journal of Thoracic Oncology

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

(2020) Mariano Provencio et al.   LANCET ONCOLOGY

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

(2018) Patrick M. Forde et al.   NEW ENGLAND JOURNAL OF MEDICINE

Initial results of pulmonary resection following neoadjuvant nivolumab in patients with resectable non-small cell lung cancer

(2018) Matthew J. Bott et al.   JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

(2017) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

(2016) Naiyer A. Rizvi et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease

(2016) J. Liu et al.   Cancer Discovery

Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data

(2014)   LANCET

Preoperative chemotherapy for non-small-cell lung cancer

(2014) Gerard G Hanna et al.   LANCET

Weeklynab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

(2012) Mark A. Socinski et al.   JOURNAL OF CLINICAL ONCOLOGY

Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non–Small-Cell Lung Cancer

(2010) Enriqueta Felip et al.   JOURNAL OF CLINICAL ONCOLOGY

Timing of Local and Distant Failure in Resected Lung Cancer: Implications for Reported Rates of Local Failure

(2010) Jessamy A. Boyd et al.   Journal of Thoracic Oncology